EP1533369B1 - Bacteriophages isolées et leur utilisation dans la nouriture ou pour l'assainissement en millieu industrielle - Google Patents

Bacteriophages isolées et leur utilisation dans la nouriture ou pour l'assainissement en millieu industrielle Download PDF

Info

Publication number
EP1533369B1
EP1533369B1 EP03026432A EP03026432A EP1533369B1 EP 1533369 B1 EP1533369 B1 EP 1533369B1 EP 03026432 A EP03026432 A EP 03026432A EP 03026432 A EP03026432 A EP 03026432A EP 1533369 B1 EP1533369 B1 EP 1533369B1
Authority
EP
European Patent Office
Prior art keywords
fsm
phage
milk
sakazakii
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03026432A
Other languages
German (de)
English (en)
Other versions
EP1533369A1 (fr
Inventor
Pieter Breeuwer
Catherine Boissin-Delaporte
Henricus Joosten
Annick Lardeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03026432A priority Critical patent/EP1533369B1/fr
Application filed by Nestec SA filed Critical Nestec SA
Priority to DE60336480T priority patent/DE60336480D1/de
Priority to AT03026432T priority patent/ATE503007T1/de
Priority to ES03026432T priority patent/ES2363497T3/es
Priority to CN200480036371XA priority patent/CN1890366B/zh
Priority to PCT/EP2004/012585 priority patent/WO2005049813A1/fr
Priority to BRPI0416768-6A priority patent/BRPI0416768A/pt
Priority to ARP040104265A priority patent/AR047126A1/es
Publication of EP1533369A1 publication Critical patent/EP1533369A1/fr
Priority to CR8382A priority patent/CR8382A/es
Priority to EC2006006556A priority patent/ECSP066556A/es
Priority to CO06047629A priority patent/CO5690610A2/es
Application granted granted Critical
Publication of EP1533369B1 publication Critical patent/EP1533369B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/097—Preservation
    • A23C19/10—Addition of preservatives
    • A23C19/11—Addition of preservatives of antibiotics or bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/195—Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Definitions

  • the present invention relates to phage isolates having a strong lytic activity against Enterobacter sakazakii strains and their use as anti-microbial agent in food products, in particular infant formula, and for sanitation of factory environments.
  • Enterobacteria represent a dominant portion of the "recontamination flora" of dairy products made from pasteurised milk. Their presence often indicates inadequate sanitization and/or faulty construction of the processing equipment. Members of the genus Enterobacter are frequently found in dried products such as milk powder.
  • E. sakazakii can cause serious infections especially among very young. It has been implicated in a rare but severe form of neonatal meningitis among neonates and infants, with dried-infant formula being implicated as the mode of transmission.
  • the problem of the present invention resides in providing a food, in particular milk based products such as infant formulas, which may be safe even after storage in conditions favouring the growth of E . sakazakii. Also, the invention aims to develop a safe agent that can be used for decontamination of E. sakazakii in any food product and for sanitation of factory environments.
  • the present invention relates to the use of at least one phage isolate or cocktail as described above, for decontamination of food products and sanitation of factory environment or in the preparation of a composition intended to prevent or treat infections caused by E. sakazakii in humans or animals.
  • a major advantage of the present invention is that it provides for a decontaminant having a high specificity for E . sakazakii. It may prevent contamination and outgrowth of E. sakazakii in any food product, being particularly useful for milk based products such as infant formulas. It can also be efficient for the treatment or prevention of infections caused by E. sakazakii in humans or animals.
  • Another advantage of the present invention is that it provides an agent which helps to disinfect, clean and decontaminate working surfaces or processing equipment in factories, as well as floors; walls and the like.
  • Another advantage of the present invention is that it provides an agent that is environmentally safe and non-toxic for humans.
  • FSM-phage designates the Food Safety Microbiology bacteriophage collection (Nestlé Research Centre, Vers-chez-les-Blanc, Lausanne, Switzerland).
  • An agent for decontamination of food and sanitation of factory environment comprises at least one phage isolate with substantial lytic potential towards E. sakazakii, is concerned.
  • the phages according to the present invention may be obtained by screening candidate bacteriophages for those which infect E. sakazakii strains using the spot assay test ( Pelczar, M.J., E.C.S. Chan, and N.R. Krieg. Microbiology concepts and applications, Chapter 16 Viruses: cultivation methods, pathogencity p.436-452, McGraw-Hill, Inc. New York 1993 ), or in liquid culture ( H.W. Ackermann and M.S. DuBow. Viruses of Prokaryotes volume 1. Chapter 6. Description and identification of new phages p. 103-142. CRC Press Inc, Boca Raton, Florida, USA .).
  • the method for selecting the Bacteriophages is detailled in example 1.
  • the phage isolates may be FSM-Phage 67/33/1, FSM-Phage F, FSM-Phage 9/261, FSM-Phage F/316and FSM-Phage 73/311/2, FSM-Phage 73/261, FSM-Phage 33/33/1, FSM-Phage 28/145/2 and FSM-Phage 10/261/1.
  • the phage isolates are phages FSM-Phage 10/261/1, FSM-Phage 73/261, FSM-Phage 33/33/1, FSM-Phage 67/33/1, FSM-Phage F/316, FSM-Phage 9/261, and FSM-Phage 73/311/2 together with their corresponding propagation strains and have been deposited by way of example at the Institut Pasteur, 28 rue du Do Budapest Roux, F-75024 Paris CEDEX 15, FRANCE, on 14/11/2003, under the deposit number CNCM 1-3127, CNCM 1-3128, CNCM 1-3129, CNCM 1-3130, CNCM I- 3131, CNCM I-3132 and CNCM I-3133, respectively.
  • the phages deposited are able to lyse at least 80 % out of the E . sakazakii from the Nestlé Research Centre collection composed of 39 strains. This collection is representative for the E . sakazakii that can be found in food products, in particular infant formula.
  • coverage of about 97 per cent can be obtained by using a phage cocktail of at least two phages.
  • the phages are not able to recognize non-related bacteria such as the gram-negative lactic acid bacteria.
  • the invention relates to the use of at least one phage isolate of the invention, in any food product or nutritional supplement, for preventing contamination and outgrowth of E . sakazakii.
  • food or pharmaceuticals products are milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae or tablets, liquid suspensions, dried oral supplement, wet oral supplement, dry-tube-feeding. Methods for preparing them are common knowledge.
  • composition according to the invention may also comprise usual excipients, in particular sweeteners, flavouring agents or preservatives. It can further comprise a prebiotic and/or a probiotic microorganism.
  • compositions of the invention may be formulated according to any one of a number of techniques that are well known to this art.
  • a food composition containing at least one phage isolate according to the present invention is prepared.
  • This composition may be a nutritional complete formula, an infant formula, a dairy product, a chilled or shelf stable beverage, water, a soup, a dietary supplement, a meal replacement, a nutritional bar or a confectionery.
  • phages may be added to a dry powdered infant formula.
  • a usual food product may be enriched with at least one phage isolate according to the present invention.
  • said phage isolate may be included alone or in a phage cocktail, into a product as mentioned above in an amount of at least about 10 4 pfu (plaque forming unit)/ml or gram (depending if the phages are added in a dry or liquid state), and more preferably from about 10 6 to about 10 11 pfu/ml or gram.
  • the phage isolate may be prepared by spray-drying, freeze-drying, or in liquid sample container using the product as support material, e.g. milk powder for infant formula. It can also be used as a supplement to be mixed with the product before serving, as additional packaging (e.g. sachet).
  • phages according to the invention are performed with the objective to inhibit growth of the target bacteria.
  • Such compositions may be prepared by conventional methods.
  • the amount of phages is preferably of at least about 10 6 pfu (plaque forming unit)/ml or gram, and more preferably from about 10 6 to about 10 11 pfu/ml or gram.
  • Example 1 Selection of phages according to the invention
  • the above pre-treated samples have been tested in parallel with or without pre-amplification. Once the presence of phage is detected, they are amplified and stored.
  • Step 1 Preparation of the bacterial culture:
  • a culture of E. sakazakii having grown overnight at 30°C in Brain Heart Infusion (BHI, Oxoid CM225) is prepared, and then 0.5 ml of this culture is transferred in 4ml of fresh BHI and incubated 1h at 40°C.
  • BHI Brain Heart Infusion
  • Step 2 Add samples to bacteria:
  • Step 3 Inoculation of Petri dishes:
  • Step 5 Controls
  • Step 1- Day 1 Preparation of the bacterial culture:
  • a culture of E. sakazakii having grown overnight at 30°C in Brain Heart Infusion (BHI, Oxoid CM225) is prepared, then 0.5 ml of this culture is transferred in 4ml of fresh BHI and incubated 1h at 40°C.
  • Step 2 - Day 1 Amplification of phage in the sample:
  • Step 3 - Day 2 Centrifugation 10 min at 2500 rpm
  • Step 4 - Day 2 Preparation of the bacterial culture:
  • a culture of E. sakazakii having grown overnight at 30°C in Brain Heart Infusion (BHI, Oxoid CM225) is prepared, then 0.5 ml of this culture is transferred in 4ml of fresh BHI and incubated 1h at 40°C.
  • Step 5 - Day 2 Add samples to bacteria:
  • Step 6 - Day 2 Inoculation of Petri dishes:
  • Step 7 - Day 3 Interpretation of results: Note the presence or absence of plaques of lyses on each Petri dish.
  • Step 1 Preparation of the bacterial culture:
  • a culture of E. sakazakii having grown overnight at 30°C in Brain Heart Infusion (BHI, Oxoid CM225) is prepared, then 0.5 ml of this culture is transferred in 4ml of fresh BHI and incubated 1h at 40°C.
  • Step 2 Amplification of the pfu:
  • Step 3 Centrifugation 10 min at 2500rpm.
  • Step 4 Filtration of the supernatant using a filter of 0.20 ⁇ m (to eliminate bacteria)
  • Step 5 Preparation of the bacterial culture:
  • a culture of E . sakazakii having grown overnight at 30°C in Brain Heart Infusion (BHI, Oxoid CM225) is prepared and then 0.5 ml of this culture is transferred in 4ml of fresh BHI and incubated 1h at 40°C.
  • BHI Brain Heart Infusion
  • Step 6 Add phages to bacteria:
  • Step 7 Inoculation of Petri dishes:
  • Step 8 Interpretation of results:
  • Step 1 Preparation of aliquots:
  • Step 2 Addition of glycerol:
  • Step 3 Quickly freeze the tubes in liquid nitrogen
  • Step 4 Storage of the tubes in a freezer at -20°C
  • Step 1 Day 0: Preparation of the bacterial culture:
  • a culture of E. sakazakii having grown overnight at 30°C in Brain Heart Infusion (BHI, Oxoid CM225) is prepared.
  • Step 2 Day 1: Preparation of the bacterial culture:
  • microtiterplates Leave the microtiterplates from the refrigerator. Add in negative control wells, 180 ⁇ l BHI and in test wells, 160 ⁇ l BHI plus 20 ⁇ l phage suspension (final concentration of 8 log pfu/ml). Read at 620nm the optical density (time zero) of the microtiterplate by using a microplate reader Multiskan MCC340. Plates are then incubated at 37°C in ambient air and OD 620nm was read after 6h30 and 8h30 incubation.
  • phage isolates that are active against at least 9 out of the 39 E . sakazakii strains selected from the group :FSM-16; 33; 261; 265; 266,269;270;271;272;273;274;280;281;284;286;288;290;292;297;298;300; 303; 305; 308; 309; 311; 313; 314; 316; 318; 322; 323; 1360; 1387/2NL; MC7; MC8; MC9; MM10 and MM11, are selected.
  • the 11 phage isolates (including the phages FSM-Phage 67/33/1, FSM-Phage F/316, FSM-Phage 9/261, and FSM-Phage 73/311/2) are presented in Table 3. Some phage isolates proved to be efficient against at least 20 out of the 39 bacterial strains.
  • the said phages were further tested on liquid medium in order to select the phage isolates according to the present invention.
  • the results are then presented in Table 4.
  • some phage isolate recognize more than 80 % of the 39 E. sakazakii strains.
  • Other isolates recognize not even 10 % of the strains tested.
  • the phages isolates that are further active in liquid medium against at least 9 out of the 39 E.
  • FSM-16 selected from the group : FSM-16; FSM-33; FSM-261; FSM-265; FSM-266, FSM-269; FSM-270; FSM-271; FSM-272; FSM-273; FSM-274; FSM-280; FSM-281; FSM-284; FSM-286; FSM-288; FSM-290; FSM-292; FSM-297; FSM-298; FSM-300; FSM-303; FSM-305; FSM-308; FSM-309; FSM-311; FSM-313; FSM-314; FSM-316; FSM-318; FSM-322; FSM-323; FSM-1360; FSM-1387-2NL; FSM-MC7; FSM-MC8; FSM-MC9; FSM-MM10 and FSM-MM11, are selected phage isolates that can be used in the present invention.
  • the following 8 phage isolates FSM-Phage 67/33/1 (CNCM I-3130), FSM-Phage F/316 (CNCM I-3131), FSM-Phage 9/261 (CNCM I-3132), and FSM-Phage 73/311/2 (CNCM I-3133), FSM-Phage 73/261(CNCM I-3128), FMS 33/33/1, (CNCM I-3129) FSM-Phage 28/145/2, FSM-Phage 10/261/1 (CNCM I-3127).
  • Example 2 Evaluation of bacteriophage cocktail efficacy against a mix of various strains of Enterobacter sakazakii in BHI and Reconstituted Infant Formula (RIF)
  • the phage isolate cocktail containing FSM_phage 67/33/1 (CNCM I-3130), FSM_phage F/316 (CNCM I-3131), FSM_phage 9/261 (CNCM I-3132) and FSM_phage 73/311/2 (CNCM I-3133) has been tested.
  • a variable amount of each phage is added to the tubes containing E. sakazakii mix to reach a final concentration of about 8 log pfu/ml.
  • Negative control without addition of phage (BHI or RIF 9.9ml + E. sakazakii mix 100 ⁇ l) is also included.
  • E. sakazakii strains FSM-145, 286, 290, 305 and 1387/2NL (see examples 1 and 2)
  • Individual overnight culture (18h at 30°C) of these strains is centrifuged at 3000rpm for 10min at 4°C.
  • Cell pellet is harvested and diluted in BHI to reach a cell concentration of about 8 log cfu/ml.
  • a mix of these strains is carried-out by mixing equal quantities of each stock.
  • Stainless steel disc of 1cm 2 are plunged in the bacterial solution prepared as described in step 1. Leave at room temperature under gentle shaking for 1h.
  • step 6 is applied on some discs.
  • Step 4 Addition of phage cocktail
  • Half of stainless steel discs are plunged in a 8 log pfu/ml phage cocktail solution containing the following phages: FSM_phage 67/33/1 (CNCM I-3130), FSM_phage F/316 (CNCM I-3131), FSM_phage 9/261 (CNCM I-3132) and FSM_phage 73/311/2 (CNCM I-3133). Leave the container at room temperature under gentle shaking for 6 hours. Withdraw some discs at various intervals for bacteria enumeration. In parallel, controls without phage added are carried-out.
  • Step 5 Washing
  • Step 6 Cell detachment and enumeration
  • step 5 put each disc into tubes containing 9ml TS. Tubes are placed into sonication bath (filled with water and ice mix) for 1min at 50KHz afterwards; tubes are agitated for 10 seconds by using a Vortex. Cell enumeration is performed using a standard plating method.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nutrition Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (12)

  1. Un isolat de phage avec essentiellement un potentiel lytique envers E. Sakazakii sélectionné parmi le groupe constitué de CNCM I-3127, CNCM I-3128, CNCM 1-3129, CNCM I-3130, CNCM I-3131, CNCM I-3132, et CNCM I-3133.
  2. Un cocktail de phages contenant au moins un isolat de phage selon la revendication 1.
  3. Un produit alimentaire contenant au moins un isolat de phage ou un cocktail de phages avec essentiellement un potentiel lytique envers E. Sakazakii, l'isolat de phage ou le cocktail de phages étant selon la revendication 1 ou 2, ledit aliment étant de la forme d'un produit à base de lait, une composition nutritionnelle, un aliment pour animal domestique, un supplément diététique ou un n'importe quel aliment ayant un risque de contamination par E. Sakazakii.
  4. Un produit alimentaire selon la revendication 3,
    dans lequel le produit à base de lait est du lait fermenté, du yogourt, du lait caillé, du fromage, du fromage frais, un produit fermenté, du lait emprésuré, une boisson, une poudre à base de lait, une formule pour nourrisson ou une formule pour nourrisson en poudre et séchée.
  5. Un produit alimentaire selon l'une des revendications 3 à 4,
    dans lequel l'isolat de phage ou le cocktail de phages est dans une quantité effective pour prévenir la contamination et l'excroissance de E. Sakazakii dans ledit produit.
  6. Un produit alimentaire selon la revendication 5,
    dans lequel l'isolat de phage est présent dans une quantité d'au moins 1.104 pfu par ml, ou gramme si solide, du produit alimentaire.
  7. Un agent pour la décontamination de produit alimentaire par la prévention de la contamination et de l'excroissance de E. Sakazakii et l'assainissement de milieu industriel, qui comprend une quantité effective d'au moins un isolat de phage ou cocktail de phages selon l'une des revendications 1 à 2.
  8. Un agent selon la revendication 7,
    dans lequel l'isolat de phage est présent dans une quantité d'au moins 1.104 pfu par ml, ou gramme si solide.
  9. Un agent selon l'une des revendications 7 ou 8,
    dans lequel le produit alimentaire est un produit à base de lait, tel que du lait fermenté, du yogourt, du lait caillé, du fromage, du fromage frais, des produits fermentés à base de lait, du lait emprésuré, des boissons, des poudres à base de lait, une formule pour nourrisson, une formule pour nourrisson en poudre et séchée ; un produit fermenté non-laitier ; un produit à base de soja, une formule nutritionnelle, un produit laitier, une boisson rafraîchie ou réfrigérée ou de longue conservation, eau, soupe, un supplément diététique, un substitut de repas, une barre nutritionnelle ou une confiserie, un produit alimentaire pour animal domestique, une boisson sucrée ou édulcorée, une crème glacée, une barre de confiserie, des flocons de céréales pour petit-déjeuner ou des barres ou un supplément nutritionnel pour alimentation clinique or n'importe quel aliment à risque de contamination par E. Sakazakii.
  10. Utilisation d'au moins un isolat de phage ou cocktail de phages selon l'une des revendications 1 à 2, pour la décontamination de produits alimentaires et l'assainissement de milieu industriel, le produit alimentaire étant un produit à base de lait, tel que du lait fermenté, du yogourt, du lait caillé, du fromage, du fromage frais, des produits fermentés à base de lait, du lait emprésuré, des boissons, des poudres à base de lait, une formule pour nourrisson, une formule pour nourrisson en poudre et séchée ; un produit fermenté non-laitier ; un produit à base de soja, une formule nutritionnelle, un produit laitier, une boisson rafraîchie ou réfrigérée ou de longue conservation, eau, soupe, un supplément diététique, un substitut de repas, une barre nutritionnelle ou une confiserie, un produit alimentaire pour animal domestique, une boisson sucrée ou édulcorée, une crème glacée, une barre de confiserie, des flocons de céréales pour petit-déjeuner ou des barres ou un supplément nutritionnel pour alimentation clinique or n'importe quel aliment à risque de contamination par E. Sakazakii.
  11. Utilisation d'au moins un isolat de phage selon l'une des revendications 1 à 2, dans la préparation d'une composition destinée à prévenir ou traiter des infections causées par E. Sakazakii chez les humains ou les animaux, l'isolat de phage étant présent dans une quantité effective pour prévenir la contamination et l'excroissance de E. Sakazakii.
  12. L'utilisation selon l'une des revendications 10 à 11,
    dans lequel l'isolat de phage ou le cocktail de phages est utilisé dans une quantité d'au moins 1.104 pfu par ml.
EP03026432A 2003-11-19 2003-11-19 Bacteriophages isolées et leur utilisation dans la nouriture ou pour l'assainissement en millieu industrielle Expired - Lifetime EP1533369B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE60336480T DE60336480D1 (de) 2003-11-19 2003-11-19 Isolierte Bakteriophage und ihre Verwendung in Lebensmitteln oder zur Sanierung der Fabrik-Umgebung
AT03026432T ATE503007T1 (de) 2003-11-19 2003-11-19 Isolierte bakteriophage und ihre verwendung in lebensmitteln oder zur sanierung der fabrik- umgebung
ES03026432T ES2363497T3 (es) 2003-11-19 2003-11-19 Fagos aislados y su utilización como desinfectante en alimentos y para la higienización de un entorno de fabricación.
EP03026432A EP1533369B1 (fr) 2003-11-19 2003-11-19 Bacteriophages isolées et leur utilisation dans la nouriture ou pour l'assainissement en millieu industrielle
PCT/EP2004/012585 WO2005049813A1 (fr) 2003-11-19 2004-11-06 Phages isoles et leur utilisation en tant que desinfectants dans les aliments et pour l'assainissement d'environnements d'usines
BRPI0416768-6A BRPI0416768A (pt) 2003-11-19 2004-11-06 fagos isolados e seu uso como desinfetantes em alimentos ou para sanitização de ambientes de fábricas
CN200480036371XA CN1890366B (zh) 2003-11-19 2004-11-06 分离的噬菌体和它们作为食品中消毒剂或用于工厂环境卫生的用途
ARP040104265A AR047126A1 (es) 2003-11-19 2004-11-18 Fagos aislados y su uso como desinfectante en alimento o para la higienizacion del ambiente industrial
CR8382A CR8382A (es) 2003-11-19 2006-05-05 Fagos aislados y su uso como desinfectante en alimento o para la higienizacion del ambiente industrial
EC2006006556A ECSP066556A (es) 2003-11-19 2006-05-10 Fagos aislados y su uso como desinfectante en alimento o para la higienización del ambiente industrial
CO06047629A CO5690610A2 (es) 2003-11-19 2006-05-18 Fagos aislados y su uso como desinfectante en alimento o para la higienizacion del ambiente industrial

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03026432A EP1533369B1 (fr) 2003-11-19 2003-11-19 Bacteriophages isolées et leur utilisation dans la nouriture ou pour l'assainissement en millieu industrielle

Publications (2)

Publication Number Publication Date
EP1533369A1 EP1533369A1 (fr) 2005-05-25
EP1533369B1 true EP1533369B1 (fr) 2011-03-23

Family

ID=34429383

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03026432A Expired - Lifetime EP1533369B1 (fr) 2003-11-19 2003-11-19 Bacteriophages isolées et leur utilisation dans la nouriture ou pour l'assainissement en millieu industrielle

Country Status (11)

Country Link
EP (1) EP1533369B1 (fr)
CN (1) CN1890366B (fr)
AR (1) AR047126A1 (fr)
AT (1) ATE503007T1 (fr)
BR (1) BRPI0416768A (fr)
CO (1) CO5690610A2 (fr)
CR (1) CR8382A (fr)
DE (1) DE60336480D1 (fr)
EC (1) ECSP066556A (fr)
ES (1) ES2363497T3 (fr)
WO (1) WO2005049813A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2130440A1 (fr) * 2008-06-06 2009-12-09 N.V. Nutricia Inhibition de croissance E. Sakazakii
US20110027417A1 (en) 2009-07-31 2011-02-03 Patrick Joseph Corrigan Process for Dusting Animal Food
AU2010212280B2 (en) * 2009-08-12 2015-09-24 Buddhist Tzu Chi Medical Foundation Phage of acinetobacter Baumannii
KR101188611B1 (ko) * 2010-01-08 2012-10-08 가천대학교 산학협력단 사카자키 균의 생육을 저해하는 효과를 가지는 가축 분변 유래의 독성파아지 및 이를 이용한 생육 제어 방법
CN101775444A (zh) * 2010-03-05 2010-07-14 中国检验检疫科学研究院 阪崎肠杆菌噬菌体效价快速测定方法
SG190087A1 (en) 2010-11-02 2013-06-28 Abbott Lab Stable concentrated liquid human milk fortifier
EP2465509A1 (fr) * 2010-11-23 2012-06-20 Nestec S.A. Composition comprenant des oligosaccharides pour le traitement des infections des voies respiratoires aiguës
RU2749423C2 (ru) 2015-04-28 2021-06-10 Марс, Инкорпорейтед Способ получения стерилизованного влажного кормового продукта для домашних животных
CN107828743B (zh) * 2017-11-09 2019-09-17 扬州大学 一种阪崎肠杆菌噬菌体EspYZU05及其用途
CN109730235A (zh) * 2019-02-01 2019-05-10 珠海横琴普罗恩能医用食品有限公司 一种用于医用食品的防腐剂
CN112063732B (zh) * 2020-09-17 2022-05-31 扬州大学 一种能够特异性识别阪崎肠杆菌存活细胞的快速定量检测方法及其引物
CN114369579B (zh) * 2021-09-27 2023-03-14 东北农业大学 一株高效裂解阪崎克罗诺杆菌的噬菌体及其应用
CN115011564B (zh) * 2022-01-19 2023-06-20 华中农业大学 一株能够裂解阪崎肠杆菌的广谱噬菌体lpcs28及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322783B1 (en) * 1996-08-26 2001-11-27 Seishi Takahashi Bacteriophages, method for screening same and bactericidal compositions using same, and detection kits using same
AU2002366854A1 (en) * 2001-12-13 2003-07-09 Societe Des Produits Nestle S.A. Isolated phages and their use in food or pet food products

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance

Also Published As

Publication number Publication date
AR047126A1 (es) 2006-01-11
WO2005049813A1 (fr) 2005-06-02
ES2363497T3 (es) 2011-08-05
ATE503007T1 (de) 2011-04-15
BRPI0416768A (pt) 2007-02-27
DE60336480D1 (de) 2011-05-05
CR8382A (es) 2008-09-23
EP1533369A1 (fr) 2005-05-25
ECSP066556A (es) 2006-11-24
CO5690610A2 (es) 2006-10-31
CN1890366A (zh) 2007-01-03
CN1890366B (zh) 2011-05-11

Similar Documents

Publication Publication Date Title
EP1533369B1 (fr) Bacteriophages isolées et leur utilisation dans la nouriture ou pour l'assainissement en millieu industrielle
Joosten et al. Detection, growth, and amine-producing capacity of lactobacilli in cheese
Gardiner et al. A spray-dried culture for probiotic Cheddar cheese manufacture
El-Ziney et al. The Effect of Reuterin on Listeria monocytogenes and Escherichia coliO157: H7 in Milk and Cottage Cheese
RU2370525C2 (ru) Способ получения композиции, содержащей высушенные бактерии, и ее применение
El Kholy et al. Screening of antagonistic activity of probiotic bacteria against some food-borne pathogens
Iranmanesh et al. Isolation of lactic acid bacteria from ewe milk, traditional yoghurt and sour buttermilk in Iran.
US6746672B2 (en) Isolated bifidobacteria that produce siderophores which inhibit growth of lactococcus lactis
Delbès-Paus et al. Behavior of Escherichia coli O26: H11 in the presence of Hafnia alvei in a model cheese ecosystem
El‐Kholy et al. Microbiological Quality of Domiati Cheese and the Influence of Probiotics on the Behavior of S taphylococcus aureus and E scherichia coli O 157: H 7 in Domiati Cheese
Rukure et al. Survival and growth of Bacillus cereus during Gouda cheese manufacturing
Meera et al. Partial characterization and optimization of parameters for Bacteriocin production by Probiotic Lactic acid bacteria
KR20160063024A (ko) 락토바실러스 플란타룸 kcc-24 및 이를 포함하는 조성물
El-Shenawy et al. Antimicrobial activity of some lactic acid bacteria isolated from local environment in Egypt
Olaniyi et al. Antimicrobial characteristics of lactic acid bacteria in African yam bean-based drink.
Sameera et al. A study on microbial flora and quality of raw and pasteurized milk from Hyderabad Telangana state, India
Adam et al. Microbiological quality of some commercial dairy products and cheese analogues focused on Mideast
MXPA06005557A (en) Isolated phages and their use as disinfectant in food or for sanitation of factory environment
Vashi et al. The effect of immobilization of lactic acid bacteria in alginate coated with chitosan on their resistance to laboratory model of human gut and on antibacterial activity
Geetha et al. MICROBIOLOGICAL QUALITY AND SAFETY OF MILK AND MILK PRODUCTS
Mitjans et al. Antimicrobial effect of bacteriocin from Lactobacillus fermentum isolated from goat milk on perishable foods. San Luis. Argentina
Sulieman Starter Cultures: Nature, Types, Characteristics, Preparation and Maintenance
Skowron et al. Biofilms in dairy industry
Khudiar et al. Occurrence Bacillus subtilis and Bacillus cereus in dried milk found in Baghdad markets
Ortakci Contribution of a novel obligatory heterofermentative nonstarter Lactobacillus species to late gassy defect in cheddar cheese

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17P Request for examination filed

Effective date: 20051125

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078898

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60336480

Country of ref document: DE

Date of ref document: 20110505

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60336480

Country of ref document: DE

Effective date: 20110505

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2363497

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20110805

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20110401490

Country of ref document: GR

Effective date: 20110714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110623

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20111227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60336480

Country of ref document: DE

Effective date: 20111227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1078898

Country of ref document: HK

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20151124

Year of fee payment: 13

Ref country code: FI

Payment date: 20151111

Year of fee payment: 13

Ref country code: GR

Payment date: 20151015

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20151111

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20161014

Year of fee payment: 14

Ref country code: CH

Payment date: 20161115

Year of fee payment: 14

Ref country code: DE

Payment date: 20161116

Year of fee payment: 14

Ref country code: GB

Payment date: 20161116

Year of fee payment: 14

Ref country code: NL

Payment date: 20161110

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20161011

Year of fee payment: 14

Ref country code: SE

Payment date: 20161111

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170612

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161119

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20161130

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60336480

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20171201

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20171119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171120

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180602

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171120